How Merck Falsified the Clinical Trails of Molnupiravir to Replace Ivermectin
Executive Summary
- Merck brought out a new drug to replace Ivermectin.
- This article covers how Merck must have falsified its clinical trial for Molnupiravir.
Introduction
As Ivermectin came off its patent quite a while ago, Merck needed to develop a replacement for Ivermectin and promote the FDA to stop people from taking Ivermectin. This is justified because Merck is responsible to its shareholders to maximize profits, and the more people that took Ivermectin, the less money would flow to Merck.
Merck, the Originator of Ivermectin, Disavows Ivermectin?
These quotes are from the article. The FDA’s War Against the Truth on Ivermectin | AIER
In a statement from February, Merck, the company that originated and still sells ivermectin, agreed with the FDA that ivermectin should not be used for Covid-19.
“We do not believe that the data available support the safety and efficacy of ivermectin beyond the doses and populations indicated in the regulatory agency-approved prescribing information.”
Merck still sells Ivermectin as a generic — however, the Merck version is very expensive.
Merck did “not believe the data available support the safety and efficacy of Ivermectin” — for use as anything but as an antiparasitic because, very simply, Merck would not sell very much of its high-priced Ivermectin because it has lower-priced competition, as the drug is a generic.
Merck also knew it could introduce another drug seeking to replicate Ivermectin that it could then get a patent on and charge much more money.
This drug would eventually be named Molnupiravir.
Comparison of Different Treatments In Terms of Cost Per Life Saved
This graphic is from the website C19Early, which compiles and evaluates the studies of different treatments versus covid.
Notice that in their estimation of the cost per life saved for each treatment, Ivermectin is ranked fifth at $24 per dose. Molnupiravir is ranked 19th for $137,653.
Take a guess which one of these drugs Merck would prefer to sell.
Secondly, with a patent, Merck has a monopoly on selling Molnupiravir. In contrast, with Ivermectin, developed decades ago, Merck no longer has the patent, and most of the revenues for Ivermectin go to other drug manufacturers rather than Merck.